

Printed by Larry Page on 7/10/2015 4:45:20 PM. For personal use only. Not approved for distribution. The NCCN Biomarkers Compendium® is copyrighted by the National Comprehensive Cancer Network, Inc. All rights reserved. To view the most up-to-date version, please visit NCCN.org/biomarkers.

Disease Description:	Acute Myeloid Leukemia (AML)
Specific Indication:	
Molecular Abnormality:	CEBPA mutation
Test:	CEBPA mutation
Chromosome:	19q13.1
Gene Symbol:	CEBPA
Test Detects:	Mutation
Methodology:	
NCCN Category of Evidence:	2A
Specimen Types:	
NCCN Recommendation - Clinical Decision:	Evaluation for acute leukemia. Bone marrow with cytogenetics (karyotype +/- FISH) and molecular analysis (KIT, FLT3-ITD, NPM1, and CEBPA mutations).
Test Purpose:	Diagnostic, Prognostic
When to Test:	Evaluation for acute leukemia
Guideline Page with Test Recommendation:	AML-1 Page:6
Notes:	Molecular abnormalities (KIT, FLT3-ITD, NPM1, and CEBPA mutations) are important for prognostication in a subset of patients (category 2A) and may guide therapeutic intervention (category 2B). These are useful for patients with normal karyotype (especially FLT3-ITD, NPM1 mutations) or core binding factor leukemia (especially c-KIT mutation). Multiplex gene panels and sequencing assays are available for the assessment of other molecular abnormalities that may have prognostic impact in AML. If a test is not available at your institution, consult pathology about preserving material from the original diagnostic sample for future use at an outside reference lab after full cytogenetic data are available.
<i>Guideline: Acute Myeloid Leukemia (AML) v. 1.2015, as of 2/13/2015 4:46:20 PM NCCN Reference ID: 34</i>	

Printed by Larry Page on 7/10/2015 4:45:20 PM. For personal use only. Not approved for distribution. The NCCN Biomarkers Compendium® is copyrighted by the National Comprehensive Cancer Network, Inc. All rights reserved. To view the most up-to-date version, please visit NCCN.org/biomarkers.

Disease Description:	Acute Myeloid Leukemia (AML)
Specific Indication:	
Molecular Abnormality:	FLT3 internal tandem duplication (ITD) mutation
Test:	FLT3 internal tandem duplication (ITD) mutation
Chromosome:	13q12
Gene Symbol:	FLT3
Test Detects:	Mutation
Methodology:	
NCCN Category of Evidence:	2A
Specimen Types:	
NCCN Recommendation - Clinical Decision:	Evaluation for acute leukemia. Bone marrow with cytogenetics (karyotype +/- FISH) and molecular analysis (KIT, FLT3-ITD, NPM1, and CEBPA mutations).
Test Purpose:	Diagnostic, Prognostic
When to Test:	Evaluation for acute leukemia
Guideline Page with Test Recommendation:	AML-1 Page:6
Notes:	Molecular abnormalities (KIT, FLT3-ITD, NPM1, and CEBPA mutations) are important for prognostication in a subset of patients (category 2A) and may guide therapeutic intervention (category 2B). These are useful for patients with normal karyotype (especially FLT3-ITD, NPM1 mutations) or core binding factor leukemia (especially c-KIT mutation). Multiplex gene panels and sequencing assays are available for the assessment of other molecular abnormalities that may have prognostic impact in AML. If a test is not available at your institution, consult pathology about preserving material from the original diagnostic sample for future use at an outside reference lab after full cytogenetic data are available.
Guideline: Acute Myeloid Leukemia (AML) v. 1.2015, as of 2/13/2015 4:46:20 PM NCCN Reference ID: 35	

Printed by Larry Page on 7/10/2015 4:45:20 PM. For personal use only. Not approved for distribution. The NCCN Biomarkers Compendium® is copyrighted by the National Comprehensive Cancer Network, Inc. All rights reserved. To view the most up-to-date version, please visit NCCN.org/biomarkers.

Disease Description:	Acute Myeloid Leukemia (AML)
Specific Indication:	
Molecular Abnormality:	KIT mutation
Test:	C-KIT mutation
Chromosome:	4q12
Gene Symbol:	KIT
Test Detects:	Mutation
Methodology:	
NCCN Category of Evidence:	2A
Specimen Types:	
NCCN Recommendation - Clinical Decision:	Evaluation for acute leukemia. Bone marrow with cytogenetics (karyotype +/- FISH) and molecular analysis (KIT, FLT3-ITD, NPM1, and CEBPA mutations).
Test Purpose:	Diagnostic, Prognostic
When to Test:	Evaluation for acute leukemia
Guideline Page with Test Recommendation:	AML-1 Page:6
Notes:	Molecular abnormalities (KIT, FLT3-ITD, NPM1, and CEBPA mutations) are important for prognostication in a subset of patients (category 2A) and may guide therapeutic intervention (category 2B). These are useful for patients with normal karyotype (especially FLT3-ITD, NPM1 mutations) or core binding factor leukemia (especially c-KIT mutation). Multiplex gene panels and sequencing assays are available for the assessment of other molecular abnormalities that may have prognostic impact in AML. If a test is not available at your institution, consult pathology about preserving material from the original diagnostic sample for future use at an outside reference lab after full cytogenetic data are available.
Guideline: Acute Myeloid Leukemia (AML) v. 1.2015, as of 2/13/2015 4:46:20 PM NCCN Reference ID: 36	

Printed by Larry Page on 7/10/2015 4:45:20 PM. For personal use only. Not approved for distribution. The NCCN Biomarkers Compendium® is copyrighted by the National Comprehensive Cancer Network, Inc. All rights reserved. To view the most up-to-date version, please visit NCCN.org/biomarkers.

Disease Description:	Acute Myeloid Leukemia (AML)
Specific Indication:	
Molecular Abnormality:	NPM1 mutation
Test:	NPM1 mutation
Chromosome:	5q35
Gene Symbol:	NPM1
Test Detects:	Mutation
Methodology:	
NCCN Category of Evidence:	2A
Specimen Types:	
NCCN Recommendation - Clinical Decision:	Evaluation for acute leukemia. Bone marrow with cytogenetics (karyotype +/- FISH) and molecular analysis (KIT, FLT3-ITD, NPM1, and CEBPA mutations).
Test Purpose:	Diagnostic, Prognostic
When to Test:	Evaluation for acute leukemia
Guideline Page with Test Recommendation:	AML-1 Page:6
Notes:	Molecular abnormalities (KIT, FLT3-ITD, NPM1, and CEBPA mutations) are important for prognostication in a subset of patients (category 2A) and may guide therapeutic intervention (category 2B). These are useful for patients with normal karyotype (especially FLT3-ITD, NPM1 mutations) or core binding factor leukemia (especially c-KIT mutation). Multiplex gene panels and sequencing assays are available for the assessment of other molecular abnormalities that may have prognostic impact in AML. If a test is not available at your institution, consult pathology about preserving material from the original diagnostic sample for future use at an outside reference lab after full cytogenetic data are available.
<i>Guideline: Acute Myeloid Leukemia (AML) v. 1.2015, as of 2/13/2015 4:46:20 PM NCCN Reference ID: 37</i>	

Printed by Larry Page on 7/10/2015 4:45:20 PM. For personal use only. Not approved for distribution. The NCCN Biomarkers Compendium® is copyrighted by the National Comprehensive Cancer Network, Inc. All rights reserved. To view the most up-to-date version, please visit NCCN.org/biomarkers.

Disease Description:	Acute Myeloid Leukemia (AML)
Specific Indication:	
Molecular Abnormality:	Abnormal immunophenotypes
Test:	Immunophenotyping
Chromosome:	
Gene Symbol:	
Test Detects:	
Methodology:	Flow cytometry, IHC
NCCN Category of Evidence:	2A
Specimen Types:	
NCCN Recommendation - Clinical Decision:	Evaluation for acute leukemia. Immunophenotyping and cytochemistry
Test Purpose:	Diagnostic
When to Test:	Evaluation for acute leukemia
Guideline Page with Test Recommendation:	AML-1 Page:6
Notes:	
Guideline: Acute Myeloid Leukemia (AML) v. 1.2015, as of 2/13/2015 4:46:20 PM NCCN Reference ID: 38	

Printed by Larry Page on 7/10/2015 4:45:21 PM. For personal use only. Not approved for distribution. The NCCN Biomarkers Compendium® is copyrighted by the National Comprehensive Cancer Network, Inc. All rights reserved. To view the most up-to-date version, please visit NCCN.org/biomarkers.

Disease Description:	Acute Myeloid Leukemia (AML)
Specific Indication:	
Molecular Abnormality:	Mutations
Test:	Molecular studies (general)
Chromosome:	
Gene Symbol:	
Test Detects:	Mutation
Methodology:	
NCCN Category of Evidence:	2A
Specimen Types:	
NCCN Recommendation - Clinical Decision:	Marrow to document remission status upon hematologic recovery, including cytogenetics and molecular studies as appropriate.
Test Purpose:	Monitoring remission status
When to Test:	Post induction therapy, upon hematologic recovery
Guideline Page with Test Recommendation:	AML-8 Page:13, AML-9 Page:14, AML-D Page:24
Notes:	Relevant only in APL and Ph+ disease (AML-D) at this time
<i>Guideline: Acute Myeloid Leukemia (AML) v. 1.2015, as of 2/13/2015 4:46:20 PM NCCN Reference ID: 39</i>	

Printed by Larry Page on 7/10/2015 4:45:21 PM. For personal use only. Not approved for distribution. The NCCN Biomarkers Compendium® is copyrighted by the National Comprehensive Cancer Network, Inc. All rights reserved. To view the most up-to-date version, please visit NCCN.org/biomarkers.

Disease Description:	Acute Myeloid Leukemia (AML)
Specific Indication:	
Molecular Abnormality:	(9;22) translocation
Test:	(9;22) translocation
Chromosome:	t(9;22)
Gene Symbol:	BCR-ABL1
Test Detects:	Translocation
Methodology:	Cytogenetics
NCCN Category of Evidence:	2A
Specimen Types:	
NCCN Recommendation - Clinical Decision:	Risk status: Poor risk; Cytogenetics: t(9;22).
Test Purpose:	Classification, Prognostic
When to Test:	Evaluation for acute leukemia
Guideline Page with Test Recommendation:	AML-A Page:20
Notes:	
Guideline: Acute Myeloid Leukemia (AML) v. 1.2015, as of 2/13/2015 4:46:20 PM NCCN Reference ID: 41	

Printed by Larry Page on 7/10/2015 4:45:21 PM. For personal use only. Not approved for distribution. The NCCN Biomarkers Compendium® is copyrighted by the National Comprehensive Cancer Network, Inc. All rights reserved. To view the most up-to-date version, please visit NCCN.org/biomarkers.

Disease Description:	Acute Myeloid Leukemia (AML)
Specific Indication:	
Molecular Abnormality:	(16;16) translocation
Test:	(16;16) translocation
Chromosome:	t(16;16)
Gene Symbol:	CBFB-MYH11
Test Detects:	Translocation
Methodology:	Cytogenetics
NCCN Category of Evidence:	2A
Specimen Types:	
NCCN Recommendation - Clinical Decision:	Risk status: Favorable risk; Cytogenetics: Core binding factor: inv(16) or t(16;16) or t(8;21)
	Risk status: intermediate risk, Molecular abnormalities: t(16;16) with c-KIT mutation.
Test Purpose:	Classification, Prognostic
When to Test:	Evaluation for acute leukemia
Guideline Page with Test Recommendation:	AML-A Page:20
Notes:	
Guideline: Acute Myeloid Leukemia (AML) v. 1.2015, as of 2/13/2015 4:46:20 PM NCCN Reference ID: 43	

Printed by Larry Page on 7/10/2015 4:45:21 PM. For personal use only. Not approved for distribution. The NCCN Biomarkers Compendium® is copyrighted by the National Comprehensive Cancer Network, Inc. All rights reserved. To view the most up-to-date version, please visit NCCN.org/biomarkers.

Disease Description:	Acute Myeloid Leukemia (AML)
Specific Indication:	
Molecular Abnormality:	16 inversion
Test:	16 inversion
Chromosome:	inv(16)
Gene Symbol:	CBFB-MYH11
Test Detects:	Chromosome inversion
Methodology:	Cytogenetics
NCCN Category of Evidence:	2A
Specimen Types:	
NCCN Recommendation - Clinical Decision:	Risk status: Favorable risk; Cytogenetics: Core binding factor: inv(16) or t(16;16) or t(8;21).
Test Purpose:	Classification, Prognostic
When to Test:	Evaluation for acute leukemia
Guideline Page with Test Recommendation:	AML-A Page:20
Notes:	
Guideline: Acute Myeloid Leukemia (AML) v. 1.2015, as of 2/13/2015 4:46:20 PM NCCN Reference ID: 45	

Printed by Larry Page on 7/10/2015 4:45:21 PM. For personal use only. Not approved for distribution. The NCCN Biomarkers Compendium® is copyrighted by the National Comprehensive Cancer Network, Inc. All rights reserved. To view the most up-to-date version, please visit NCCN.org/biomarkers.

Disease Description:	Acute Myeloid Leukemia (AML)
Specific Indication:	
Molecular Abnormality:	CEBPA mutation
Test:	CEBPA mutation
Chromosome:	19q13.1
Gene Symbol:	CEBPA
Test Detects:	Mutation
Methodology:	
NCCN Category of Evidence:	2B
Specimen Types:	
NCCN Recommendation - Clinical Decision:	Risk status: Favorable risk; Molecular abnormalities: Normal cytogenetics with isolated biallelic CEBPA mutation.
Test Purpose:	Treatment decision
When to Test:	Evaluation for acute leukemia
Guideline Page with Test Recommendation:	AML-1 Page:6, AML-10 Page:15, AML-A Page:20
Notes:	
Guideline: Acute Myeloid Leukemia (AML) v. 1.2015, as of 2/13/2015 4:46:20 PM NCCN Reference ID: 46	

Printed by Larry Page on 7/10/2015 4:45:21 PM. For personal use only. Not approved for distribution. The NCCN Biomarkers Compendium® is copyrighted by the National Comprehensive Cancer Network, Inc. All rights reserved. To view the most up-to-date version, please visit NCCN.org/biomarkers.

Disease Description:	Acute Myeloid Leukemia (AML)
Specific Indication:	
Molecular Abnormality:	CEBPA mutation
Test:	CEBPA mutation
Chromosome:	19q13.1
Gene Symbol:	CEBPA
Test Detects:	Mutation
Methodology:	
NCCN Category of Evidence:	2A
Specimen Types:	
NCCN Recommendation - Clinical Decision:	Risk status: Favorable risk; Molecular abnormalities: normal cytogenetics with isolated biallelic CEBPA mutation
Test Purpose:	Classification, Prognostic
When to Test:	Evaluation for acute leukemia
Guideline Page with Test Recommendation:	AML-A Page:20
Notes:	
Guideline: Acute Myeloid Leukemia (AML) v. 1.2015, as of 2/13/2015 4:46:20 PM NCCN Reference ID: 47	

Printed by Larry Page on 7/10/2015 4:45:21 PM. For personal use only. Not approved for distribution. The NCCN Biomarkers Compendium® is copyrighted by the National Comprehensive Cancer Network, Inc. All rights reserved. To view the most up-to-date version, please visit NCCN.org/biomarkers.

Disease Description:	Acute Myeloid Leukemia (AML)
Specific Indication:	
Molecular Abnormality:	(6;9) translocation
Test:	(6;9) translocation
Chromosome:	t(6;9)
Gene Symbol:	DEK-NUP214
Test Detects:	Translocation
Methodology:	Cytogenetics
NCCN Category of Evidence:	2A
Specimen Types:	
NCCN Recommendation - Clinical Decision:	Risk status: Poor-risk; Cytogenetics: t(6;9).
Test Purpose:	Classification, Prognostic
When to Test:	Evaluation for acute leukemia
Guideline Page with Test Recommendation:	AML-A Page:20
Notes:	
Guideline: Acute Myeloid Leukemia (AML) v. 1.2015, as of 2/13/2015 4:46:20 PM NCCN Reference ID: 48	

Printed by Larry Page on 7/10/2015 4:45:21 PM. For personal use only. Not approved for distribution. The NCCN Biomarkers Compendium® is copyrighted by the National Comprehensive Cancer Network, Inc. All rights reserved. To view the most up-to-date version, please visit NCCN.org/biomarkers.

Disease Description:	Acute Myeloid Leukemia (AML)
Specific Indication:	
Molecular Abnormality:	FLT3 internal tandem duplication (ITD) mutation
Test:	FLT3 internal tandem duplication (ITD) mutation
Chromosome:	13q12
Gene Symbol:	FLT3
Test Detects:	Mutation
Methodology:	
NCCN Category of Evidence:	2A
Specimen Types:	
NCCN Recommendation - Clinical Decision:	Risk status: Poor-risk; Molecular abnormalities: normal cytogenetics with FLT3-ITD mutation.
Test Purpose:	Classification, Prognostic
When to Test:	Evaluation for acute leukemia
Guideline Page with Test Recommendation:	AML-A Page:20
Notes:	
Guideline: Acute Myeloid Leukemia (AML) v. 1.2015, as of 2/13/2015 4:46:20 PM NCCN Reference ID: 50	

Printed by Larry Page on 7/10/2015 4:45:21 PM. For personal use only. Not approved for distribution. The NCCN Biomarkers Compendium® is copyrighted by the National Comprehensive Cancer Network, Inc. All rights reserved. To view the most up-to-date version, please visit NCCN.org/biomarkers.

Disease Description:	Acute Myeloid Leukemia (AML)
Specific Indication:	
Molecular Abnormality:	FLT3 internal tandem duplication (ITD) mutation
Test:	FLT3 internal tandem duplication (ITD) mutation
Chromosome:	13q12
Gene Symbol:	FLT3
Test Detects:	Mutation
Methodology:	
NCCN Category of Evidence:	2B
Specimen Types:	
NCCN Recommendation - Clinical Decision:	Risk status: Poor-risk; Molecular abnormalities: normal cytogenetics with FLT3-ITD mutation.
Test Purpose:	Treatment decision
When to Test:	Evaluation for acute leukemia
Guideline Page with Test Recommendation:	AML-1 Page:6, AML-10 Page:15, AML-A Page:20
Notes:	
Guideline: Acute Myeloid Leukemia (AML) v. 1.2015, as of 2/13/2015 4:46:20 PM NCCN Reference ID: 51	

Printed by Larry Page on 7/10/2015 4:45:21 PM. For personal use only. Not approved for distribution. The NCCN Biomarkers Compendium® is copyrighted by the National Comprehensive Cancer Network, Inc. All rights reserved. To view the most up-to-date version, please visit NCCN.org/biomarkers.

Disease Description:	Acute Myeloid Leukemia (AML)
Specific Indication:	
Molecular Abnormality:	FLT3 tyrosine kinase domain mutation D835
Test:	FLT3 tyrosine kinase domain mutation D835
Chromosome:	13q12
Gene Symbol:	FLT3
Test Detects:	Mutation
Methodology:	
NCCN Category of Evidence:	2A
Specimen Types:	
NCCN Recommendation - Clinical Decision:	FLT3-ITD mutations are considered to confer a significantly poorer outcome in patients with normal karyotype. There is controversy as to whether FLT3-TKD mutations carry an equally poor prognosis
Test Purpose:	Classification, Prognostic
When to Test:	Evaluation for acute leukemia
Guideline Page with Test Recommendation:	AML-A Page:20
Notes:	

Guideline: Acute Myeloid Leukemia (AML) v. 1.2015, as of 2/13/2015 4:46:20 PM NCCN Reference ID: 52

Printed by Larry Page on 7/10/2015 4:45:21 PM. For personal use only. Not approved for distribution. The NCCN Biomarkers Compendium® is copyrighted by the National Comprehensive Cancer Network, Inc. All rights reserved. To view the most up-to-date version, please visit NCCN.org/biomarkers.

Disease Description:	Acute Myeloid Leukemia (AML)
Specific Indication:	
Molecular Abnormality:	KIT mutation
Test:	C-KIT mutation
Chromosome:	4q12
Gene Symbol:	KIT
Test Detects:	Mutation
Methodology:	
NCCN Category of Evidence:	2B
Specimen Types:	
NCCN Recommendation - Clinical Decision:	Risk status: Intermediate risk; Molecular abnormalities: t(8;21), inv(16), t(16;16) with c-KIT mutation.
Test Purpose:	Treatment decision
When to Test:	Evaluation for acute leukemia
Guideline Page with Test Recommendation:	AML-1 Page:6, AML-10 Page:15, AML-A Page:20
Notes:	
Guideline: Acute Myeloid Leukemia (AML) v. 1.2015, as of 2/13/2015 4:46:20 PM NCCN Reference ID: 54	

Printed by Larry Page on 7/10/2015 4:45:21 PM. For personal use only. Not approved for distribution. The NCCN Biomarkers Compendium® is copyrighted by the National Comprehensive Cancer Network, Inc. All rights reserved. To view the most up-to-date version, please visit NCCN.org/biomarkers.

Disease Description:	Acute Myeloid Leukemia (AML)
Specific Indication:	
Molecular Abnormality:	KIT mutation
Test:	C-KIT mutation
Chromosome:	4q12
Gene Symbol:	KIT
Test Detects:	Mutation
Methodology:	
NCCN Category of Evidence:	2A
Specimen Types:	
NCCN Recommendation - Clinical Decision:	Risk status: Intermediate risk; Molecular abnormalities: t(8;21), inv(16), t(16;16) with c-KIT mutation.
Test Purpose:	Classification, Prognostic
When to Test:	Evaluation for acute leukemia
Guideline Page with Test Recommendation:	AML-A Page:20
Notes:	

Guideline: Acute Myeloid Leukemia (AML) v. 1.2015, as of 2/13/2015 4:46:20 PM NCCN Reference ID: 55

Printed by Larry Page on 7/10/2015 4:45:21 PM. For personal use only. Not approved for distribution. The NCCN Biomarkers Compendium® is copyrighted by the National Comprehensive Cancer Network, Inc. All rights reserved. To view the most up-to-date version, please visit NCCN.org/biomarkers.

Disease Description:	Acute Myeloid Leukemia (AML)
Specific Indication:	
Molecular Abnormality:	Translocations
Test:	Translocations
Chromosome:	11q23
Gene Symbol:	MLL
Test Detects:	Translocation
Methodology:	Cytogenetics
NCCN Category of Evidence:	2A
Specimen Types:	
NCCN Recommendation - Clinical Decision:	Risk status: Poor-risk; Cytogenetics: 11q23 abnormalities.
Test Purpose:	Classification, Prognostic
When to Test:	Evaluation for acute leukemia
Guideline Page with Test Recommendation:	AML-A Page:20
Notes:	
Guideline: Acute Myeloid Leukemia (AML) v. 1.2015, as of 2/13/2015 4:46:20 PM NCCN Reference ID: 57	

Printed by Larry Page on 7/10/2015 4:45:21 PM. For personal use only. Not approved for distribution. The NCCN Biomarkers Compendium® is copyrighted by the National Comprehensive Cancer Network, Inc. All rights reserved. To view the most up-to-date version, please visit NCCN.org/biomarkers.

Disease Description:	Acute Myeloid Leukemia (AML)
Specific Indication:	
Molecular Abnormality:	(9;11) translocation
Test:	(9;11) translocation
Chromosome:	t(9;11)
Gene Symbol:	MLLT3-MLL
Test Detects:	Translocation
Methodology:	Cytogenetics
NCCN Category of Evidence:	2A
Specimen Types:	
NCCN Recommendation - Clinical Decision:	Risk status: Intermediate risk; Cytogenetics: t(9;11).
Test Purpose:	Classification, Prognostic
When to Test:	Evaluation for acute leukemia
Guideline Page with Test Recommendation:	AML-A Page:20
Notes:	
Guideline: Acute Myeloid Leukemia (AML) v. 1.2015, as of 2/13/2015 4:46:20 PM NCCN Reference ID: 59	

Printed by Larry Page on 7/10/2015 4:45:21 PM. For personal use only. Not approved for distribution. The NCCN Biomarkers Compendium® is copyrighted by the National Comprehensive Cancer Network, Inc. All rights reserved. To view the most up-to-date version, please visit NCCN.org/biomarkers.

Disease Description:	Acute Myeloid Leukemia (AML)
Specific Indication:	
Molecular Abnormality:	NPM1 mutation
Test:	NPM1 mutation
Chromosome:	5q35
Gene Symbol:	NPM1
Test Detects:	Mutation
Methodology:	
NCCN Category of Evidence:	2B
Specimen Types:	
NCCN Recommendation - Clinical Decision:	Risk status: Favorable risk; Molecular abnormalities: normal cytogenetics with NPM1 mutation in absence of FLT3 ITD.
Test Purpose:	Treatment decision
When to Test:	Evaluation for acute leukemia
Guideline Page with Test Recommendation:	AML-1 Page:6, AML-10 Page:15, AML-A Page:20
Notes:	
Guideline: Acute Myeloid Leukemia (AML) v. 1.2015, as of 2/13/2015 4:46:20 PM NCCN Reference ID: 60	

Printed by Larry Page on 7/10/2015 4:45:21 PM. For personal use only. Not approved for distribution. The NCCN Biomarkers Compendium® is copyrighted by the National Comprehensive Cancer Network, Inc. All rights reserved. To view the most up-to-date version, please visit NCCN.org/biomarkers.

Disease Description:	Acute Myeloid Leukemia (AML)
Specific Indication:	
Molecular Abnormality:	NPM1 mutation
Test:	NPM1 mutation
Chromosome:	5q35
Gene Symbol:	NPM1
Test Detects:	Mutation
Methodology:	
NCCN Category of Evidence:	2A
Specimen Types:	
NCCN Recommendation - Clinical Decision:	Risk status: Favorable risk; Molecular abnormalities: normal cytogenetics with NPM1 mutation in absence of FLT3 ITD.
Test Purpose:	Classification, Prognostic
When to Test:	Evaluation for acute leukemia
Guideline Page with Test Recommendation:	AML-A Page:20
Notes:	
Guideline: Acute Myeloid Leukemia (AML) v. 1.2015, as of 2/13/2015 4:46:20 PM NCCN Reference ID: 61	

Printed by Larry Page on 7/10/2015 4:45:22 PM. For personal use only. Not approved for distribution. The NCCN Biomarkers Compendium® is copyrighted by the National Comprehensive Cancer Network, Inc. All rights reserved. To view the most up-to-date version, please visit NCCN.org/biomarkers.

Disease Description:	Acute Myeloid Leukemia (AML)
Specific Indication:	
Molecular Abnormality:	3 inversion
Test:	3 inversion
Chromosome:	inv(3)
Gene Symbol:	RPN1-EVI1
Test Detects:	Chromosome inversion
Methodology:	Cytogenetics
NCCN Category of Evidence:	2A
Specimen Types:	
NCCN Recommendation - Clinical Decision:	Risk status: Poor-risk; Cytogenetics: inv(3).
Test Purpose:	Classification, Prognostic
When to Test:	Evaluation for acute leukemia
Guideline Page with Test Recommendation:	AML-A Page:20
Notes:	
Guideline: Acute Myeloid Leukemia (AML) v. 1.2015, as of 2/13/2015 4:46:20 PM NCCN Reference ID: 63	

Printed by Larry Page on 7/10/2015 4:45:22 PM. For personal use only. Not approved for distribution. The NCCN Biomarkers Compendium® is copyrighted by the National Comprehensive Cancer Network, Inc. All rights reserved. To view the most up-to-date version, please visit NCCN.org/biomarkers.

Disease Description:	Acute Myeloid Leukemia (AML)
Specific Indication:	
Molecular Abnormality:	3 translocation
Test:	3 translocation
Chromosome:	t(3;3)
Gene Symbol:	RPN1-EVI1
Test Detects:	Translocation
Methodology:	Cytogenetics
NCCN Category of Evidence:	2A
Specimen Types:	
NCCN Recommendation - Clinical Decision:	Risk status: Poor-risk; Cytogenetics: t(3;3).
Test Purpose:	Classification, Prognostic
When to Test:	Evaluation for acute leukemia
Guideline Page with Test Recommendation:	AML-A Page:20
Notes:	
Guideline: Acute Myeloid Leukemia (AML) v. 1.2015, as of 2/13/2015 4:46:20 PM NCCN Reference ID: 65	

Printed by Larry Page on 7/10/2015 4:45:22 PM. For personal use only. Not approved for distribution. The NCCN Biomarkers Compendium® is copyrighted by the National Comprehensive Cancer Network, Inc. All rights reserved. To view the most up-to-date version, please visit NCCN.org/biomarkers.

Disease Description:	Acute Myeloid Leukemia (AML)
Specific Indication:	
Molecular Abnormality:	(8:21) translocation
Test:	(8:21) translocation
Chromosome:	t(8;21)
Gene Symbol:	RUNX1-RUNX1T1
Test Detects:	Translocation
Methodology:	Cytogenetics
NCCN Category of Evidence:	2A
Specimen Types:	
NCCN Recommendation - Clinical Decision:	Risk status: Favorable risk; Cytogenetics: Core binding factor: inv(16) or t(16;16) or t(8;21)
Test Purpose:	Classification, Prognostic
When to Test:	Evaluation for acute leukemia
Guideline Page with Test Recommendation:	AML-A Page:20
Notes:	
Guideline: Acute Myeloid Leukemia (AML) v. 1.2015, as of 2/13/2015 4:46:20 PM NCCN Reference ID: 67	

Printed by Larry Page on 7/10/2015 4:45:22 PM. For personal use only. Not approved for distribution. The NCCN Biomarkers Compendium® is copyrighted by the National Comprehensive Cancer Network, Inc. All rights reserved. To view the most up-to-date version, please visit NCCN.org/biomarkers.

Disease Description:	Acute Myeloid Leukemia (AML)
Specific Indication:	
Molecular Abnormality:	Chromosomal abnormalities
Test:	Cytogenetics
Chromosome:	
Gene Symbol:	
Test Detects:	Chromosomal abnormalities
Methodology:	Cytogenetics, FISH
NCCN Category of Evidence:	2A
Specimen Types:	
NCCN Recommendation - Clinical Decision:	Evaluation for acute leukemia. Bone marrow with cytogenetics (karyotype +/- FISH)
Test Purpose:	Diagnostic
When to Test:	Evaluation for acute leukemia
Guideline Page with Test Recommendation:	AML-1 Page:6
Notes:	
Guideline: Acute Myeloid Leukemia (AML) v. 1.2015, as of 2/13/2015 4:46:20 PM NCCN Reference ID: 68	

Printed by Larry Page on 7/10/2015 4:45:22 PM. For personal use only. Not approved for distribution. The NCCN Biomarkers Compendium® is copyrighted by the National Comprehensive Cancer Network, Inc. All rights reserved. To view the most up-to-date version, please visit NCCN.org/biomarkers.

Disease Description:	Acute Myeloid Leukemia (AML)
Specific Indication:	
Molecular Abnormality:	5 deletion
Test:	5 deletion
Chromosome:	-5
Gene Symbol:	
Test Detects:	Chromosome deletion
Methodology:	Cytogenetics
NCCN Category of Evidence:	2A
Specimen Types:	
NCCN Recommendation - Clinical Decision:	Risk status: Poor-risk; Cytogenetics: -5.
Test Purpose:	Classification, Prognostic
When to Test:	Evaluation for acute leukemia
Guideline Page with Test Recommendation:	AML-A Page:20
Notes:	
Guideline: Acute Myeloid Leukemia (AML) v. 1.2015, as of 2/13/2015 4:46:20 PM NCCN Reference ID: 70	

Printed by Larry Page on 7/10/2015 4:45:22 PM. For personal use only. Not approved for distribution. The NCCN Biomarkers Compendium® is copyrighted by the National Comprehensive Cancer Network, Inc. All rights reserved. To view the most up-to-date version, please visit NCCN.org/biomarkers.

Disease Description:	Acute Myeloid Leukemia (AML)
Specific Indication:	
Molecular Abnormality:	5q deletion
Test:	5q deletion
Chromosome:	del(5q)
Gene Symbol:	
Test Detects:	Chromosome deletion
Methodology:	Cytogenetics
NCCN Category of Evidence:	2A
Specimen Types:	
NCCN Recommendation - Clinical Decision:	Risk status: Poor-risk; Cytogenetics: del(5q).
Test Purpose:	Classification, Prognostic
When to Test:	Evaluation for acute leukemia
Guideline Page with Test Recommendation:	AML-A Page:20
Notes:	
Guideline: Acute Myeloid Leukemia (AML) v. 1.2015, as of 2/13/2015 4:46:20 PM NCCN Reference ID: 72	

Printed by Larry Page on 7/10/2015 4:45:22 PM. For personal use only. Not approved for distribution. The NCCN Biomarkers Compendium® is copyrighted by the National Comprehensive Cancer Network, Inc. All rights reserved. To view the most up-to-date version, please visit NCCN.org/biomarkers.

Disease Description:	Acute Myeloid Leukemia (AML)
Specific Indication:	
Molecular Abnormality:	7 deletion
Test:	7 deletion
Chromosome:	-7
Gene Symbol:	
Test Detects:	Chromosome deletion
Methodology:	Cytogenetics
NCCN Category of Evidence:	2A
Specimen Types:	
NCCN Recommendation - Clinical Decision:	Risk status: Poor-risk; Cytogenetics: -7.
Test Purpose:	Classification, Prognostic
When to Test:	Evaluation for acute leukemia
Guideline Page with Test Recommendation:	AML-A Page:20
Notes:	
Guideline: Acute Myeloid Leukemia (AML) v. 1.2015, as of 2/13/2015 4:46:20 PM NCCN Reference ID: 74	

Printed by Larry Page on 7/10/2015 4:45:22 PM. For personal use only. Not approved for distribution. The NCCN Biomarkers Compendium® is copyrighted by the National Comprehensive Cancer Network, Inc. All rights reserved. To view the most up-to-date version, please visit NCCN.org/biomarkers.

Disease Description:	Acute Myeloid Leukemia (AML)
Specific Indication:	
Molecular Abnormality:	7q deletion
Test:	7q deletion
Chromosome:	del(7q)
Gene Symbol:	
Test Detects:	Chromosome deletion
Methodology:	Cytogenetics
NCCN Category of Evidence:	2A
Specimen Types:	
NCCN Recommendation - Clinical Decision:	Risk status: Poor-risk; Cytogenetics: del(7q).
Test Purpose:	Classification, Prognostic
When to Test:	Evaluation for acute leukemia
Guideline Page with Test Recommendation:	AML-A Page:20
Notes:	
Guideline: Acute Myeloid Leukemia (AML) v. 1.2015, as of 2/13/2015 4:46:20 PM NCCN Reference ID: 76	

Printed by Larry Page on 7/10/2015 4:45:22 PM. For personal use only. Not approved for distribution. The NCCN Biomarkers Compendium® is copyrighted by the National Comprehensive Cancer Network, Inc. All rights reserved. To view the most up-to-date version, please visit NCCN.org/biomarkers.

Disease Description:	Acute Myeloid Leukemia (AML)
Specific Indication:	
Molecular Abnormality:	Chromosomal abnormalities
Test:	Cytogenetics
Chromosome:	
Gene Symbol:	
Test Detects:	Chromosomal abnormalities
Methodology:	Karyotype analysis
NCCN Category of Evidence:	2A
Specimen Types:	
NCCN Recommendation - Clinical Decision:	Marrow to document remission status upon hematologic recovery, including cytogenetics and molecular studies as appropriate.
Test Purpose:	Monitoring remission status
When to Test:	Post induction therapy, upon hematologic recovery
Guideline Page with Test Recommendation:	AML-8 Page:13, AML-9 Page:14, AML-D Page:24
Notes:	
Guideline: Acute Myeloid Leukemia (AML) v. 1.2015, as of 2/13/2015 4:46:20 PM NCCN Reference ID: 77	

Printed by Larry Page on 7/10/2015 4:45:22 PM. For personal use only. Not approved for distribution. The NCCN Biomarkers Compendium® is copyrighted by the National Comprehensive Cancer Network, Inc. All rights reserved. To view the most up-to-date version, please visit NCCN.org/biomarkers.

Disease Description:	Acute Myeloid Leukemia (AML)
Specific Indication:	
Molecular Abnormality:	Chromosomal abnormalities, complex karyotype, monosomal karyotype
Test:	Cytogenetics
Chromosome:	
Gene Symbol:	
Test Detects:	Gross chromosomal abnormalities
Methodology:	Cytogenetics
NCCN Category of Evidence:	2A
Specimen Types:	
NCCN Recommendation - Clinical Decision:	Risk status: Poor-risk; Cytogenetics: Complex (≥ 3 clonal chromosomal abnormalities); Monosomal karyotype.
Test Purpose:	Classification, Prognostic
When to Test:	Evaluation for acute leukemia
Guideline Page with Test Recommendation:	AML-A Page:20
Notes:	
Guideline: Acute Myeloid Leukemia (AML) v. 1.2015, as of 2/26/2015 2:54:54 PM NCCN Reference ID: 79	

Printed by Larry Page on 7/10/2015 4:45:22 PM. For personal use only. Not approved for distribution. The NCCN Biomarkers Compendium® is copyrighted by the National Comprehensive Cancer Network, Inc. All rights reserved. To view the most up-to-date version, please visit NCCN.org/biomarkers.

Disease Description:	Acute Myeloid Leukemia (AML)
Specific Indication:	
Molecular Abnormality:	Trisomy of chromosome 8
Test:	Trisomy of chromosome 8
Chromosome:	+8
Gene Symbol:	
Test Detects:	Trisomy
Methodology:	Cytogenetics
NCCN Category of Evidence:	2A
Specimen Types:	
NCCN Recommendation - Clinical Decision:	Risk status: Intermediate-risk; Cytogenetics: +8 alone.
Test Purpose:	Classification, Prognostic
When to Test:	Evaluation for acute leukemia
Guideline Page with Test Recommendation:	AML-A Page:20
Notes:	
Guideline: Acute Myeloid Leukemia (AML) v. 1.2015, as of 2/13/2015 4:46:20 PM NCCN Reference ID: 81	